S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
BREAKING: Tiny biotech successfully treats blindness (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
BREAKING: Tiny biotech successfully treats blindness (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
BREAKING: Tiny biotech successfully treats blindness (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
BREAKING: Tiny biotech successfully treats blindness (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run

Intellia Therapeutics (NTLA) Stock Forecast, Price & News

$43.36
-0.10 (-0.23%)
(As of 06/8/2023 ET)
Compare
Today's Range
$42.60
$44.00
50-Day Range
$34.58
$45.76
52-Week Range
$32.44
$76.45
Volume
704,038 shs
Average Volume
943,570 shs
Market Capitalization
$3.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.53

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
85.7% Upside
$80.53 Price Target
Short Interest
Healthy
6.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.92mentions of Intellia Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.33) to ($5.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

92nd out of 986 stocks

Diagnostic Substances Industry

2nd out of 15 stocks


NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

CRSP Jun 2023 64.000 put
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Intellia Therapeutics (NASDAQ: NTLA)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
12 Analysts Have This to Say About Intellia Therapeutics
See More Headlines

NTLA Price History

NTLA Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.53
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+85.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-474,190,000.00
Net Margins
-804.94%
Pretax Margin
-804.94%

Debt

Sales & Book Value

Annual Sales
$53.48 million
Book Value
$15.70 per share

Miscellaneous

Free Float
84,704,000
Market Cap
$3.82 billion
Optionable
Optionable
Beta
1.84

Key Executives

  • John M. LeonardJohn M. Leonard
    President, Chief Executive Officer & Director
  • Glenn GoddardGlenn Goddard
    Chief Financial, Treasurer & Accounting Officer
  • Laura Sepp-LorenzinoLaura Sepp-Lorenzino
    Chief Scientific Officer & Executive VP
  • David LebwohlDavid Lebwohl
    Chief Medical Officer & Executive Vice President
  • Eliana Clark
    Chief Technology Officer & Executive VP













NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2023?

18 brokers have issued 12-month price targets for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $39.00 to $120.00. On average, they predict the company's stock price to reach $80.53 in the next twelve months. This suggests a possible upside of 85.7% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2023?

Intellia Therapeutics' stock was trading at $34.89 at the beginning of 2023. Since then, NTLA shares have increased by 24.3% and is now trading at $43.36.
View the best growth stocks for 2023 here
.

Are investors shorting Intellia Therapeutics?

Intellia Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 5,940,000 shares, a decline of 13.0% from the April 30th total of 6,830,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 5.4 days.
View Intellia Therapeutics' Short Interest
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, May, 4th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.41) by $0.24. The business earned $12.60 million during the quarter, compared to analyst estimates of $11.76 million. Intellia Therapeutics had a negative net margin of 804.94% and a negative trailing twelve-month return on equity of 41.67%. Intellia Therapeutics's revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.96) EPS.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.18%), BlackRock Inc. (8.34%), State Street Corp (4.02%), Sumitomo Mitsui Trust Holdings Inc. (3.53%), Nikko Asset Management Americas Inc. (3.53%) and Wellington Management Group LLP (3.37%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $43.36.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.82 billion and generates $53.48 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 485 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -